Coherus Biosciences | CHRS - Nettoeinkommen





Nettoeinkommen Veränderung Datum
AbbVie USD 4.22B 605M 2026-09
Acadia Pharmaceuticals USD 53.52M 22.02M 2026-09
Akebia Therapeutics USD -12.24M 12.78M 2025-12
ALKERMES USD 16.29M 15.79M 2026-09
Alnylam Pharmaceuticals USD 2.17B 2B 2026-09
Amarin USD -1.22M 6.51M 2025-12
Amgen USD 3.86B 1.49B 2026-09
Baxter International USD 294M 168M 2026-09
Biogen USD 97.5M 222M 2026-06
BioMarin Pharmaceutical USD -122.83M 167.59M 2026-09
Bristol-Myers Squibb USD 2.16B 1.16B 2026-09
Coherus Biosciences USD -37.64M 2.11M 2025-12
Eli Lilly USD 7.1B 301M 2026-06
Fujifilm JPY 67.71B 30.33B 2026-09
Gilead Sciences USD -10.5B 12.52B 2026-06
Ironwood Pharmaceuticals USD 3.19M 457K 2024-12
Merck USD 5.07B 6.4B 2026-09
Myriad Genetics USD -7.9M 19.5M 2025-12
Pacira USD 325.3M 320.65M 2026-09
Perrigo USD -27.5M 102M 2026-09
Pfizer USD 3.24B 3.49B 2026-09
PTC Therapeutics USD 83.5M 86.3M 2026-06
Regeneron Pharmaceuticals USD 1.3B 569.7M 2026-06
Sarepta Therapeutics USD -28.46M 23.57M 2026-09
Teva Pharmaceutical Industries USD 233M 809M 2026-09
Vertex Pharmaceuticals USD 653.6M 446.2M 2026-09
Xencor USD -21.73M 107.19M 2026-06
Zoetis USD 591M 100M 2026-09